New Urine Test Boosts Forecasting of Treatment Outcomes in Bladder Cancer

Stanford University scientists developed a molecular urine analysis that can distinguish bladder cancer patients who need immunotherapy from those already cured by surgical removal, transforming treatment planning for roughly 60,000 Americans diagnosed yearly with early-stage disease.

The screening can detect cancer recurrence months ahead of visible tumor growth, enabling physicians to strengthen interventions for vulnerable patients while avoiding unnecessary treatment for others already disease-free.

Early-stage bladder cancer returns frequently despite prompt intervention. Following tumor removal, patients showing high-risk characteristics undergo six weekly BCG immunotherapy bladder treatments aimed at preventing disease comeback. Surgery alone cures some individuals while others experience cancer return even after receiving immunotherapy.

Medical teams lacked dependable ways to separate these groups, leading most intermediate and high-risk patients toward immunotherapy regardless of whether residual cancer actually persisted. BCG causes serious adverse reactions and faces persistent worldwide availability constraints.

Publishing their work in Cell, Stanford investigators built a urine screening test measuring tumor DNA fragments but discovered an unexpected obstacle. Aging bladder tissue in healthy individuals accumulates cancer-linked genetic changes researchers named “clonal cystopoiesis.” These benign cells shed modified DNA into urine that highly sensitive assays can misidentify as malignancy.

Scientists developed computational filtering that removes these background genetic alterations, permitting reliable identification of actual remaining malignant cells. Joseph Liao from Stanford’s Urology Department explains that the improved method can spot microscopic disease persisting following intervention while eliminating confusion from benign tissue mutations that undermined previous efforts.

Testing prospective patients receiving surgery plus BCG demonstrated remarkable prediction accuracy. Individuals showing detectable cancer DNA after finishing immunotherapy confronted virtually guaranteed disease return. Patients whose cancer DNA vanished achieved outstanding results. Screening revealed recurrence danger in numerous instances where conventional bladder examinations found nothing abnormal.

Examining specimens collected pre-surgery, post-surgery, and post-immunotherapy exposed three separate molecular outcome categories. One group showed cancer DNA vanishing after surgical excision without additional treatment. Another exhibited residual cancer DNA following surgery that diminished after receiving immunotherapy.

A third displayed cancer DNA levels remaining steady or climbing after immunotherapy completion. Distinguishing these categories allowed investigation into why malignancies respond uniquely to different interventions. Surgery-resistant tumors expressed genes promoting cellular proliferation and tissue infiltration.

Immunotherapy-responsive tumors carried elevated genetic mutation counts plus active immune engagement, rendering them recognizable to defensive systems. During worldwide BCG scarcity, screening could direct immunotherapy toward individuals gaining maximum advantage while exempting those molecularly cleared by surgery.

Intervention could intensify promptly for maximum-risk individuals ahead of observable tumor reappearance, potentially blocking advancement toward lethal forms. Validating the discovery through expanded investigations could transform bladder cancer management from standardized approaches toward individualized frameworks where simple urine collection guides decisions about continuing or stopping therapy.

As many more companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) and academic institutions engage in research aimed at increasing efficacy and access to immunotherapy, the fight against cancer is bound to notch significant successes in the coming years.

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN